PharmaShots | Incisive News in 3 Shots

Subscribe Now

Finch-2 P-III study

Gilead and Galapagos NV Reports Filgotinib (JAK1i) achieve 1EP and 2EP in FINCH-2 P-III study for the Treatment of RA

Gilead and Galapagos NV Reports Filgotinib (JAK1i) achieve 1EP and 2EP in FINCH-2 P-III study for the Treatment of RA

September 12, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us